RIMLS PhD retreat registration is open23 January 2020
Yearly, RIMLS PhD candidates gather for the two-day PhD Retreat. Apart from the science, this event is highly valued for the opportunity to meet and get to know fellow PhD candidates during the social activities. Early bird registration and abstract submission deadline: 4 March 2020.
NWO Open Competition Domain Science - XS grant for Ronald van Rij and Jenny van der Wijst21 January 2020
NWO Domain Science has awarded Ronald van Rij, theme Infectious diseases and global health and Jennny van der Wijst, theme Renal disorders an XS grant. The XS category emphatically strives to encourage curiosity-driven and bold research involving a relatively quick analysis of a promising idea.
Resistance of malaria parasites against artemisinin explained7 January 2020
Malaria parasites that are resistant to the commonly used malaria medicine artemisinin are a growing problem. How these parasites become resistant has now been uncovered by the RIMLS group of Richard Bartfai, theme Infectious diseases and global health, and published in Science.
JPI-AMR grant for Quirijn de Mast and Marien de Jonge6 January 2020
The JPI-AMR grant ‘Diagnostics and surveillance of antimicrobial resistance: development of tools, technologies and methods for global use’ has been awarded to Quirijn de Mast and Marien de Jonge), the Charles University Prague and the Kilimanjaro Christian Medical Centre in Moshi, Tanzania.
Newly appointed Junior Principal Clinicians3 December 2019
The appointed junior Principal Clinician for RIMLS are Heidi Zweers-van Essen and Jenneke Leentjens. These caregivers are at the forefront of renewing patient care and take the lead in the development and realization of the Radboudumc vision.
Two RIHS researchers in top 1 percent by citations28 November 2019
Bart-Jan Kullberg and Jacques Meis, made it to this year’s list of highly cited researchers. Researchers in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.
Five RIMLS researchers in top 1 percent by citations26 November 2019
Leo Joosten, Jos van der Meer, Mihai Netea, Henk Stunnenberg and Frank van de Veerdonk, made it to this year’s list of highly cited researchers. Researchers in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.
RIMLS 25 years jubilee festival The Future is Yesterday3 October 2019
Together with more than 250 colleagues and alumni we celebrated 25 years of research into the molecular mechanisms of disease. During this exciting and informal event, we not only took a trip down memory lane, but also looked ahead to the next 25 years and beyond…...
Radboud-led collaboration generates innovative candidate drug against malaria19 September 2019
A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch when the psoriasis drug discovery programme came to a dead end.
Radboud study on Dirty Money wins Ig Nobel Prize17 September 2019
By shaking hands we are exchanging bacteria. Does this happen without direct hand-to-hand contact, for example when paying with paper money? Andreas Voss, clinical microbiologist at Radboudumc and CWZ, and colleagues in the United States received an Ig Nobel Prize for research into dirty money.
Four Veni grants for junior RIMLS researchers22 July 2019
Four junior researchers, affiliated to the RIMLS, have each received a Veni grant of 250,000 Euro from NWO. Our researchers received this prestigious grant for their remarkable and original talent and their ability to carry out innovative research.
4,8 million euros for prevention of tuberculosis among people with diabetes in Africa16 July 2019
Reinout van Crevel and Lindsey te Brake have received European funding of 4.8 million euros to lead an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB.
Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies18 June 2019
Exome sequencing may provide a genetic diagnosis in a significant number of patients in a single genetic test. Alexander Hoischen and Mihai Netea, theme Infectious diseases and global health, and colleagues, published their results in Genome Medicine.
Developing malaria gametocytes under attack6 June 2019
In Science Translational Medicine, researchers from the group of Teun Bousema and international colleagues have revealed previously unknown targets of natural human antibody responses that are found on the surfaces of red blood cells infected with malaria parasites.
The XN-30 hematology analyzer for rapid sensitive detection of malaria a diagnostic accuracy study6 June 2019
In BMC Medicine Annelies Post, Berenger Kaboré, Isaie Reuling and colleagues described a new method of malaria detection using whole blood: the XN-30 is a new hematology analyzer which simultaneously provides a complete blood count and quantification of malaria parasitemia, allowing rapid treatment.
1.6 million euros for Radboud university medical center in new study into shorter tuberculosis treatment5 June 2019
The study is meant to reveal whether a shorter treatment using a new combination of four different antibiotics could be as effective as the regular, longer treatment for tuberculosis (TB).
Three VIDI grants for RIMLS researchers24 May 2019
Matthijs Jore, Daniele Tauriello and Johannes Textor are each to receive up to 800,000 euros to develop an innovative research theme and to build up their own research group. NWO is awarding the Vidi grant as part of the Innovational Research Incentives Scheme.
Minocycline to treat pulmonary Mycobacterium avium complex disease9 May 2019
In Journal of Antimicrobial Chemotherapy Mike Ruth, Jakko van Ingen and colleagues showed that minocycline may be useful to treat pulmonary diseases caused by Mycobacterium avium complex bacteria. This is important as few drugs are active against this disease and treatment outcomes are very poor.
Removal of sialic acid from platelets responsible for thrombocytopenia in dengue23 April 2019
In the PLoS Pathogens Quirijn de Mast and his colleagues showed that excessive binding of the coagulation protein von Willebrand factor leads to removal of sialic acid from platelets and platelet clearance.
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.
Interacting non-specific immunological effects of BCG and Tdapf vaccinations5 April 2019
In a randomized trial Mihai Netea and colleagues aim to investigate the non-specific immunological effects of BCG and DTP-containing vaccines on the immune response to unrelated pathogens. They have published their findings in Clinical Infectious Diseases.
Impulsivity and infectious diseases among female prisoners in Indonesia Knowledge transfer alone not sufficient for controlling infectious diseases28 March 2019
Unprotected sexual contact and intravenous drug use are important routes of infection for infectious diseases such as HIV, hepatitis B and C and syphilis.
Importance of prospective studies in pregnant and breastfeeding women living with HIV14 March 2019
In Clinical Infectious Diseases Angela Colbers, Stein Schalkwijk and David Burger give considerations on how to effectively evaluate aspects of clinical pharmacology required for safe and effective treatment to optimize pharmacotherapy during pregnancy and breastfeeding.
Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis5 March 2019
In Neurology Anneleen Berende, Roy Kessels, Bart-Jan Kullberg and colleagues showed that longer-term antibiotic treatment did not lead to better cognitive performance compared to a 2-week regimen in patients with Lyme disease-attributed persistent symptoms.
15 million Euro to identify new drug targets for HIV28 February 2019
André van der Ven and Mihai Netea, theme Infectious diseases and global health, and colleagues, will receive 15 million Euro from pharmaceutical company ViiV Healthcare for research into new ways to fight the HIV virus. The aim of the HIV 2000+ project is to identify new drug targets for HIV.